12:00 AM
Feb 18, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Dolutegravir regulatory update

FDA accepted and granted Priority Review to an NDA from ViiV for dolutegravir to treat HIV infection in patients ages 12 and over. The PDUFA date is Aug. 17. ViiV submitted regulatory applications for the HIV...

Read the full 170 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >